Posts tagged with ‘Management’

Search for:

Syntrix to present at 2025 Life Science Innovation Northwest (LSINW)
ASCO 2024 selects SX-682 for oral podium presentation of positive first-in-class efficacy results in patients with metastatic melanoma
New study finds SX-682 leads to “unprecedented” response and cures in pancreatic cancer models
First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
New Study Points to SX-682 as Novel Strategy to Broadly Increase the Effectiveness of Therapies Targeting the RAS/RAF/MEK/ERK Signaling Pathway in Non-Small Cell Lung Cancer

Syntrix Pharmaceuticals
215 Clay Street NW
Suite B-5
Auburn, WA 98001

Syntrix to present at 2025 Life Science Innovation Northwest (LSINW)
ASCO 2024 selects SX-682 for oral podium presentation of positive first-in-class efficacy results in patients with metastatic melanoma

TEL: 253-833-8009
FAX: 253-833-8127 email: info@syntrixbio.com